1Y Close · As of Aug 26, 2026
CJ Bioscience operates in the Professional Services sector.
Legal name: CJ Bioscience
In fiscal year 2025, CJ Bioscience (311690) reported revenue of 3.7 billion KRW, up 6.5% from 3.5 billion KRW a year earlier.
Operating profit was -24.8 billion KRW and net income was -24.0 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 50.3 billion KRW, with a P/B of 0.94.
These figures can be verified in the DART filing (receipt no. 20260316001695).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 3.7B | -24.8B | -24.0B |
| 2024 | 3.5B | -34.2B | -32.8B |
| 2023 | 5.6B | -32.1B | -22.9B |
| 2022 | 4.1B | -33.2B | -34.9B |
| 2021 | 4.4B | -10.1B | -19.3B |
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-14 | Payment and Dispute Resolution |